

Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS

Washington, D.C. 20231

FILING DATE FIRST NAMED INVENTOR ATTORNEY DOCKET NO. APPLICATION NO. М 316082000121 09/194,164 04/09/99 DAN **EXAMINER** Г HM22/0602 BANSAL, G SUSAN K LEHNHARDT MORRISON & FOERSTER ART UNIT PAPER NUMBER 1290 AVENUE OF THE AMERICAS NEW YORK NY 10104-0012 1642 DATE MAILED: 06/02/00

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks

Application No. 3081 00/194/64
NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING
NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

 This application clearly falls to comply with the requirements of 33 attention is directed to these regulations, published at 1114 OG 2 18230, May 1, 1990. 	7 C.F.R. 1.821-1.825. Applicant's 9, May 15, 1990 and at 55 FR
2. This application does not contain, as a separate part of the d Listing" as required by 37 C.F.R. 1.821(c).	lisclosure on paper copy, a *Sequence
3. A copy of the "Sequence Listing" in computer readable form 37 C.F.R. 1.821(e).	has not been submitted as required by
4. A copy of the "Sequence Listing" in computer readable form content of the computer readable form does not comply with and/or 1.823, as indicated on the attached copy of the market	
5. The computer readable form that has been filed with this appand/or unreadable as indicated on the attached CRF Diskett computer readable form must be submitted as required by 3	e Pioniem Rabott A Culturus.
6. The paper copy of the "Sequence Listing" is not the same as "Sequence Listing" as required by 37 C.F.R. 1.821(e).	s the computer readable from of the
7. Other: Applicant should follow the format of the attached sain the parent application be used to create a CRF in this application.	mple statement to request that the CRF filed
Applicant Must Provide:	
An <u>initial</u> or substitute computer readable form (CRF) copy of t	the "Sequence Listing".
-	
An <u>Initial</u> or substitute paper copy of the "Sequence Listing", as into the specification.	well as an amendment directing its entry
A statement that the content of the paper and computer reada applicable, include no new matter, as required by 37 C.F.R. 1. 1.825(b) or 1.825(d).	able copies are the same and, where .821(e) or 1.821(f) or 1.821(g) or
For questions regarding compliance to these requirem	ents, please contact
For Rules Interpretation, call (703) 308-4216 For CRF Submission Help, call (703) 308-4212 For Patentin software help, call (703) 308-6856 PLEASE RETURN A COPY OF THIS NOTICE	
TELEVOL VETOKIN W COLL OF TUIS MOTIO	E WITH YOUR RESPONSE



emark Office Patent and ? R OF PATENTS AND TRADEMARKS Washington,

FILING DATE

SERIAL NUMBER

FIRST NAMED APPLICANT

ATTORNEY DOCKET NO.

EXAMINER	
ART UNIT	PAPER NUMBER
·	
	•
DATE MAILED:	

Please find below a communication from the EXAMINER in charge of this application Commissioner of Patents

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 CFR 1.821 through 1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures.

Applicant is given ONE MONTH, or THIRTY DAYS, whichever is longer, from the mailing date of this letter within which to comply with the sequence rules, 37 CFR 1.821 - 1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 CFR 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a). In no case may an applicant extend the period for reply beyond the SIX MONTH statutory period. Direct the reply to the undersigned. Applicant is requested to return a copy of the attached Notice to Comply with the reply.

Any inquiry concerning this communication should be directed to Bourse at telephone number (703)305-3955.

May 31,00